US Patent 9925269 Phospholipid ether analogs as cancer-targeting drug vehicles
Patent 9925269 was granted and assigned to Cellectar on March, 2018 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 9925269 Phospholipid ether analogs as cancer-targeting drug vehicles
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.